Innate's lacutamab gains FDA breakthrough therapy designation [Yahoo! Finance]
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: Yahoo! Finance
Credit: Stock-Asso/Shutterstock. · Pharmaceutical Technology · Stock-Asso/Shutterstock. GlobalData Mon, February 17, 2025 at 2:07 PM GMT+1 2 min read In This Article IPH.PA Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary syndrome. Lacutamab is a first-in-class antibody designed to target killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) and induce cytotoxicity. It is being tested in clinical trials for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma. The FDA's designation follows positive results from the Phase I study and the Phase II TELLOMAK trial, which showed lacutamab's efficacy and safety in patients who ha
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare ConferenceBusiness Wire
- Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments [Seeking Alpha]Seeking Alpha
- Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome [Yahoo! Finance]Yahoo! Finance
- Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary SyndromeBusiness Wire
- Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.MarketBeat